Affinivax Revenue and Competitors
Estimated Revenue & Valuation
- Affinivax's estimated annual revenue is currently $4.3M per year.
- Affinivax's estimated revenue per employee is $77,500
- Affinivax's total funding is $377.5M.
Employee Data
- Affinivax has 55 Employees.
- Affinivax grew their employee count by -68% last year.
Affinivax's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Sr Director Manufacturing | Reveal Email/Phone |
2 | Associate Scientist | Reveal Email/Phone |
Affinivax Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Affinivax?
Affinivax is a clinical stage biotechnology company developing a next generation approach in vaccine technologies to design both preventive and therapeutic vaccines that provide broader protection against infectious and other immune mediated diseases.
keywords:N/A
$377.5M
Total Funding
55
Number of Employees
$4.3M
Revenue (est)
-68%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Affinivax News
Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines designed to induce a broad and...
Following the closing of the transaction with Astellas, ASP3772 would become the most advanced vaccine candidate in Affinivax's pipeline, along...
Affinivax, Inc., a Cambridge, MA-based clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, closed a $226m Series C financing. The round was co-led by new investors Rock Springs Capital and ...
After getting off a meaty $120 million round in April, the height of the first wave of COVID-19 infections in the West, Affinivax is a clear indicator that infectious disease and vaccine work is here to stay. Sponsored by Agilent Technologies How would you like to win free bench space at Lab C ...
Affinivax, Inc., a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS platform, today announced the closing of a $226 million Series C financing, co-led by new investors Rock Springs Capital and Foresite Capital. Additional new investor ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.7M | 55 | 31% | $153M |
#2 | $8.5M | 55 | 49% | N/A |
#3 | N/A | 55 | 400% | N/A |
#4 | $15M | 56 | 17% | N/A |
#5 | $11.1M | 56 | 22% | N/A |